{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:42:51Z","timestamp":1789684971698,"version":"4.0.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,16]]},"DOI":"10.7759\/cureus.80671","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T19:42:51Z","timestamp":1742154171000},"source":"Crossref","is-referenced-by-count":2,"title":["Acute Duodenal Ulcer Perforation Following Tirzepatide Treatment: A Case Report"],"prefix":"10.7759","author":[{"given":"Maho","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tsujigiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Uwafuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis T","year":"2022","unstructured":"Karagiannis T, Avgerinos I, Liakos A, et al.. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022, 65:1251-61. 10.1007\/s00125-022-05715-4","journal-title":"Diabetologia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46091","article-title":"Tirzepatide-induced gastrointestinal manifestations: a systematic review and meta-analysis","volume":"15","author":"Karrar HR","year":"2023","unstructured":"Karrar HR, Nouh MI, Nouh YI, et al.. Tirzepatide-induced gastrointestinal manifestations: a systematic review and meta-analysis. Cureus. 2023, 15:e46091. 10.7759\/cureus.46091","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/cc9983","article-title":"Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes","volume":"15","author":"Deane AM","year":"2011","unstructured":"Deane AM, Summers MJ, Zaknic AV, et al.. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care. 2011, 15:R35. 10.1186\/cc9983","journal-title":"Crit Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-197607000-00016","article-title":"Suppression of gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP) and vasoactive intestinal polypeptide (VIP)","volume":"184","author":"Villar HV","year":"1976","unstructured":"Villar HV, Fender HR, Rayford PL, et al.. Suppression of gastrin release and gastric secretion by gastric inhibitory polypeptide (GIP) and vasoactive intestinal polypeptide (VIP). Ann Surg. 1976, 184:97-102. 10.1097\/00000658-197607000-00016","journal-title":"Ann Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0459","article-title":"GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models","volume":"70","author":"Borner T","year":"2021","unstructured":"Borner T, Geisler CE, Fortin SM, et al.. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2021, 70:2545-53. 10.2337\/db21-0459","journal-title":"Diabetes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/351464-acute-duodenal-ulcer-perforation-following-tirzepatide-treatment-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T19:42:52Z","timestamp":1742154172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/351464-acute-duodenal-ulcer-perforation-following-tirzepatide-treatment-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.80671","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,16]]}}}